http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105504063-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-81 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62 |
| filingDate | 2015-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105504063-B |
| titleOfInvention | The antineoplastic amalgamation protein of a kind of alexin-albumin and its preparation and application |
| abstract | The present invention relates to the antineoplastic amalgamation proteins of a kind of alexin-albumin, and it includes with flowering structure: alexin HBD2- link peptide (G4S) 2- human serum albumin HSAï¼›Wherein the human beta-defensin 2 (HBD2) has amino acid sequence shown in SEQ ID NO:1, the human serum albumin HSA has amino acid sequence shown in SEQ ID NO:2, the new antitumoral fusion protein, have the function of albumin giant cell drink targeting and alexin HBD-2 killing tumor cell, is expected to be developed into a kind of new type antineoplastic medicine. |
| priorityDate | 2015-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 49.